26 completed, 7 unknown, 3 withdrawn, 1 active not recruiting. 38 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 38 | Completed 26, Unknown 7, Withdrawn 3, Active not recruiting 1, Terminated 1 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 4 | Completed | The University of Hong Kong | 30 | 2022-07-25 | 2024-05-08 |
| Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment Aflibercept Ophthalmic - Retinal Vein Occlusion | Phase 4 | Terminated | Wake Forest University Health Sciences | 17 | 2021-10-06 | 2025-02-24 |
| Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial Aflibercept Injection - Diabetic Retinopathy | Phase 4 | Completed | Greater Houston Retina Research | 41 | 2021-06-01 | 2025-01-23 |
| Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML [Lucentis] - Wet Macular Degeneration | Phase 4 | Withdrawn | Faculty Hospital Kralovske Vinohrady | 2021-01-04 | 2022-08-10 | |
| A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) Iluvien 0.19 MG Drug Implant, Aflibercept - Diabetic Macular Edema | Phase 4 | Active not recruiting | Alimera Sciences | 300 | 2020-08-31 | 2024-07-31 |
| Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema Dexamethasone implant, Aflibercept - Diabetic Macular Edema | Phase 4 | Completed | The Cleveland Clinic | 23 | 2020-04-10 | 2026-07-29 |
| One Year Trial Evaluating Safety of Ozurdex With Eylea Ozurdex, Eylea - Diabetic Macular Edema | Phase 4 | Completed | Texas Retina Associates | 50 | 2019-06-11 | 2024-04-10 |
| Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) Aflibercept Injection - Diabetic Macular Edema | Phase 4 | Completed | Hyewon Chung | 23 | 2019-05-17 | 2024-05-29 |
| PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept aflibercept - Central Serous Chorioretinopathy, Age Related Macular Degeneration | Phase 4 | Unknown | Sunnybrook Health Sciences Centre | 90 | 2018-12-01 | 2021-01-28 |
| Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification Bevacizumab, Ranibizumab, Aflibercept - Diabetic Macular Edema, Cataract | Phase 4 | Completed | Bay Area Retina Associates | 16 | 2018-11-15 | 2025-09-12 |
| Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion Aflibercept Injection [Eylea], Ranibizumab Injection [Lucentis] - Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | St. Erik Eye Hospital | 110 | 2018-10-18 | 2024-10-28 |
| Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Aflibercept, Targeted laser therapy - Diabetic Retinopathy | Phase 4 | Completed | University of Sydney | 48 | 2017-06-15 | 2022-05-31 |
| Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Intravitreal aflibercept - Age Related Macular Degeneration, Diabetic Macular Edema | Phase 4 | Unknown | Unity Health Toronto | 168 | 2017-02-28 | 2021-04-28 |
| Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Aflibercept Injection - Diabetic Macular Edema | Phase 4 | Unknown | Maisonneuve-Rosemont Hospital | 40 | 2016-11-01 | 2017-03-27 |
| 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. Ranibizumab, Aflibercept - Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2016-09-01 | 2017-04-28 | |
| Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Aflibercept - Diabetic Macular Edema (DME) | Phase 4 | Completed | Hadassah Medical Organization | 48 | 2016-05-24 | 2018-09-14 |
| Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study aflibercept - Diabetic Macular Edema | Phase 4 | Unknown | Unity Health Toronto | 50 | 2016-03-01 | 2016-01-08 |
| Intravitreal Aflibercept for Submacular Hemorrhage Vascular endothelial growth factor trap-eye - Exudative Age-related Macular Degeneration | Phase 4 | Completed | Kim's Eye Hospital | 29 | 2015-12-01 | 2019-02-21 |
| Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab aflibercept - Diabetic Retinopathy, Macular Edema | Phase 4 | Completed | Rishi Singh | 20 | 2015-10-01 | 2023-03-30 |
| Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Ranibizumab, Aflibercept - Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2015-10-01 | 2016-10-27 |
Showing 20 of 38. Sign in to see all of them.
Macular Degeneration (9) · Macular Edema (6) · Retinal Vein Occlusion (6) · Diabetic Retinopathy (4) · Wet Macular Degeneration (4) · Retinal Detachment (2) · Cataract (1) · Central Serous Chorioretinopathy (1) · Diabetes Mellitus (1) · Geographic Atrophy (1) · Neovascularization, Pathologic (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Vision Disorders (1)
Novartis Pharmaceuticals (4) · Unity Health Toronto (3) · Greater Houston Retina Research (2) · Hadassah Medical Organization (2) · Northern California Retina Vitreous Associates (2) · Tennessee Retina (2) · Alimera Sciences (1) · Anders Kvanta (1) · Barcelona Macula Foundation (1) · Bay Area Retina Associates (1) · Faculty Hospital Kralovske Vinohrady (1) · Gregg T. Kokame, MD (1) · Hyewon Chung (1) · Justis Ehlers (1) · Kim's Eye Hospital (1)
United States (15) · Canada (5) · Australia (2) · Germany (2) · South Korea (2) · Sweden (2) · Czechia (1) · Hong Kong (1) · Israel (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Rajeev Muni, MD (2) · Anders Kvanta, MD PhD (1) · Ashkan M Abbey, MD (1) · Brandon G Busbee, MD (1) · Caesar Luo, MD (1) · Carlos Juan Donate, MD (1) · Charles C Wykoff, MD (1) · David Boyer, MD (1) · Dennis M Marcus, MD (1) · Flavio Rezende (1) · Francisco Cabrera, MD (1) · Franco M Recchia, MD (1) · Gregg T. Kokame, MD, MMS (1)
PMID 27409478, PMID 27465105, PMID 28814412, PMID 30676617, PMID 31016030, PMID 31367468, PMID 31564356, PMID 31757691, PMID 32374423, PMID 32557168, PMID 41295257, PMID 41887289, PMID 41954487
2014 (1)